{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260601065496/en/IMFINZI%C2%AE-durvalumab-plus-IMJUDO%C2%AE-tremelimumab-actl-combined-with-lenvatinib-and-TACE-reduced-the-risk-of-disease-progression-or-death-by-30-in-embolization-eligible-unresectable-liver-cancer-in-EMERALD-3-Phase-III-trial", "message": "News view counter 769751 successfully enlarged"}